NRx Logo
  • Our Company
  • Our Therapeutic Focus
    • Our Focus on the Brain
    • Bipolar Depression & Suicidality
    • Post-Traumatic Stress Disorder
  • Our Science
    • Our Clinical Approach
    • NRX-100/NRX-101
    • Mechanism of Action
    • NMDA & 5HT2A receptors
    • Publications & Literature
  • Pipeline
  • Investors / Media
  • Investor Relations
  • Presentation
  • Clinical Trials
  • Search

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • Analyst Coverage
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Overview
  • Press Releases
  • Analyst Coverage
  • IR Calendar
  • Email Alerts
Oct 21, 2015 11:04am EDT

American Psychiatric Association Task Force Report Identifies Potential Value of NeuroRx Active Ingredient for Treatment of Depression

Jun 24, 2015 1:00pm EDT

NeuroRx Announces First Human Trial Results Targeting Sustained Treatment of Bipolar Depression & Suicidality

  • arrow_back
  • 1
  • …
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
NRx
  • Home
  • Our Company
  • Our Science
  • Pipeline
  • News & Media
  • Resources & Patient Stories
  • Investor Relations
  • Careers
  • Contact Us
  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin
  • Forward Looking Statement
  • Privacy Policy
  • Terms of Use
  • © 2022 NRx Pharmaceuticals, Inc.

  • NRx on Facebook
  • NRx on Twitter
  • NRx on Linkedin